<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients who survive a <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (MI) are at increased risk of <z:hpo ids='HP_0001699'>sudden death</z:hpo> due to fatal <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Implantable cardioverter-defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>) reduce mortality in appropriately selected patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> and left ventricular dysfunction, regardless of etiology </plain></SENT>
<SENT sid="2" pm="."><plain>Post hoc analyses from landmark trials have evaluated the effect of time (both since MI and duration of nonischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>) before <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation on the efficacy of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Time remains a clinically important variable in the decision of if and when to implant an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Future trials should focus on invasive and/or noninvasive risk stratification of patients with ischemic and nonischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> for better identification of those who would benefit from early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation, and those in whom a watch and wait approach is appropriate </plain></SENT>
</text></document>